According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
Successfully removed peanut from the child’s left lung through bronchoscopy
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Subscribe To Our Newsletter & Stay Updated
